Overview

Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease

Status:
Not yet recruiting
Trial end date:
2025-08-25
Target enrollment:
Participant gender:
Summary
This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study examines subcutaneous dose of PF-06480605 150 mg administered every 4 weeks in participants with moderate to severe active Crohn's Disease to characterize safety, efficacy, pharmacokinetics, and immunogenicity
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer